[Development of L-OHP (trade name; Elplat)].
L-OHP (INN: oxaliplatin) was created in 1976 by Dr. Kidani. The experimental tumor models showed its antitumor activities, however, clinical investigations were not conducted in Japan. It was licensed to Debiopharm in Switzerland, and obtained the marketing authorization with the indication of colorectal cancer in France in 1996, and in the USA in 2002. The marketing authorization was given with the same indication in Japan in March, 2005. L-OHP is now widely used in the world as one of the key agents for treatments of colorectal cancers like 5-FU and CPT-11.
Terada
Kiyoshi
K
Yakult Honsha Co., Ltd.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D015195:Drug Design; D005602:France; D006801:Humans; D007564:Japan; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D014481:United States
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin